Zavante Targets Resistant Urinary Infections With I.V. Version Of Existing Drug
Executive Summary
If approved, Zolyd will be the first intravenous epoxide antibiotic approved in the US, with greater potency than the oral version used first-line. Ex-US, the I.V. formulation has demonstrated a stable resistance profile.
You may also be interested in...
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.
AMR Roundtable: The Push And Pull Of Antimicrobial Development Incentives (Part 1)
The Pink Sheet spoke with CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about what's needed to boost antimicrobial drug development, including "push" and "pull" incentives for drug makers.
Keeping Track: Submissions Complete For Breakthrough Therapies From Portola And Catalyst; FDA Finally Approves Bridion, Basaglar
The latest drug development news and highlights from our FDA Performance Tracker.